Skip to main content

Table 1 Characteristics of 152 Swedish female patients with early RA included in the study

From: Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis

 

Prednisone and MTX (ACT arm)

Certolizumab Pegol and MTX (CZP arm)

Abatacept and MTX (ABA arm)

Tocilizumab and MTX (TCZ arm)

P

N

38

42

39

33

 

Age

53.42 ± 16.74

51.93 ± 14.78

54.26 ± 16.19

53.39 ± 13.17

0.928a

BMI

26.11 ± 5.81

24.97 ± 4.79

26.18 ± 4.70

25.92 ± 5.25

0.690a

Current smoker (%)

15.79%

16.67%

10.26%

24.24%

0.464b

ACPA positive (%)

84.21%

85.71%

87.18%

84.85%

0.985b

CDAI

Day 0

32.86 ± 14.51

30.53 ± 13.67

29.19 ± 19.00

27.68 ± 11.28

0.349a

Week 12

7.51 ± 6.04

5.79 ± 4.77

6.02 ± 5.62

8.09 ± 8.98

0.335a

Week 24

6.11 ± 5.69

4.25 ± 4.42

4.65 ± 5.43

6.23 ± 5.83

0.260a

Remission-w24* (%)

36.84%

52.38%

51.28%

42.42%

0.461b

EULAR-Good response-w24 (%)

78.95%

88.1%

84.62%

69.7%

0.312b

CRP

Day 0

20 (9.75–40.25)

13 (4.6–32)

8.8 (4–30)

8 (4.25-20)

0.078c

Week 24

2 (1-4.5)

1 (0.5–2.08)

2 (1-3.8)

0.5 (0.4-1)

< 0.001c

ESR

Day 0

35 (23.75–57.5)

32 (19–58)

28 (17–50)

26 (16.5-39.75)

0.273c

Week 24

11 (5.75-21)

9.5 (5.75–19.5)

11 (7–23)

2 (2–4)

< 0.001c

  1. Data was presented as mean ± SD for normally distributed variables and median (IQR) for variables with a skewed distribution
  2. ACT, Active Conventional Therapy arm; CZP, Certolizumab Pegol arm; ABA, Abatacept arm; TCZ, Tocilizumab arm; MTX, Methotrexate; BMI, Body Mass Index; ACPA, Anticitrullinated peptide antibody; CDAI, Clinical Disease Activity Index; EULAR, European Alliance of Associations for Rheumatology; CRP, C Reactive Protein; ESR, Erythrocyte Sedimentation Rate
  3. aOne-way ANOVA
  4. bPearson Chi-square
  5. cKruskal–Wallis test
  6. *Remission was defined as CDAI ≤ 2.8